What is Nouscom?
Nouscom is at the forefront of cancer immunotherapy, specializing in the creation of engineered viral vectored vaccines and oncolytic viruses. The company leverages proprietary platforms to design cancer vaccines capable of encoding multiple tumor neoantigens, thereby amplifying the body's immune response against cancerous cells. With operational bases in Basel, Switzerland, and Rome, Italy, Nouscom is dedicated to advancing both off-the-shelf and personalized immunotherapies for a spectrum of cancer types, aiming to significantly improve patient prognoses through safe and effective therapeutic solutions.
How much funding has Nouscom raised?
Nouscom has raised a total of $142.2M across 3 funding rounds:
Series A
$13.6M
Series B
$46.6M
Series C
$82M
Series A (2016): $13.6M with participation from LSP Ventures and Versant Ventures
Series B (2017): $46.6M led by Life Sciences Partners, Versant Ventures, 5AM Ventures, and Abingworth
Series C (2024): $82M supported by X-Gen Ventures, Angelini Ventures, Revelation Partners, Bpifrance, and Andera Partners
Key Investors in Nouscom
Life Sciences Partners
Life Sciences Partners (LSP) is a prominent European venture capital firm specializing in the life sciences sector. They are known for backing innovative biotechnology and pharmaceutical companies from early to late stages, providing both capital and strategic guidance to help build world-class organizations.
Versant Ventures
Versant Ventures is a global venture capital firm dedicated to building and funding transformative biotechnology companies. With a significant track record, they invest in early-stage opportunities, leveraging their deep scientific and operational expertise to support entrepreneurs in bringing novel therapies to market.
5AM Ventures
5AM Ventures is a life science-focused venture capital firm that actively supports early-stage biotech and healthcare innovators. They partner closely with founders to shape companies, fund rigorous scientific research, and facilitate the development of new therapies for patients.
What's next for Nouscom?
The recent major strategic investment positions Nouscom for accelerated growth and the advancement of its pipeline. This capital infusion is expected to fuel further research and development, potentially enabling the company to expand its clinical trial programs and broaden its therapeutic reach. The company's focus on novel viral vector technology suggests a strategic direction towards enhancing the efficacy of cancer immunotherapies, with an eye on future commercialization and market penetration in the competitive oncology landscape.
See full Nouscom company page
